Creso Pharma has expanded its distribution agreement with nutritional supplements company Route2 Pharm to enable its hemp-derived therapeutic products to be sold under the Cannaqiz and Cannadol brands in Ecuador.

The move gives the company access to the rapidly growing Latin American CBD market which is expected to grow to more than US$300 million by 2024.

Creso Pharma non-executive chairman Adam Blumenthal said: “The evolving regulations in Ecuador and the broader Latin American and Caribbean region present a tremendous opportunity for both our human and animal products.”